ERBB2 and breast cancer: BC subtypes expressing hormone receptors (Luminal A, Luminal B, and HER2+) associate with good/intermediate prognosis, and their clinical management includes endocrine therapy alone or in combination with chemotherapy if there exists the risk of recurrence.